A new health screening method developed by Renatek, a Japanese company, is set to launch in December 2024. The test, called the Metal Balance Test, requires only 6 milliliters of blood to evaluate the risk of cancer and mild cognitive impairment. The service will be available at the Oshukansho Clinic in Gifu City.
The test analyzes metal levels in the blood to detect early signs of disease. It is designed to provide a quick and non-invasive way to assess health risks. The clinic will begin accepting reservations for the test in December. Patients will receive results that highlight potential risks related to cancer and cognitive decline.
Renatek has been working on this technology for several years. The company has focused on developing innovative diagnostic tools that improve early detection. This test is part of a broader initiative to make health screening more accessible and efficient. The launch follows successful trials in clinical settings, which showed the test’s accuracy in identifying risk factors. The company aims to expand the service to other locations in the future.
